Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

Shares of this drugmaker have returned -19.4% over the past month versus the Zacks S&P 500 composite's -12.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs ...

Shares of this drugmaker have returned -24.4% over the past month versus the Zacks S&P 500 composite's -5.6% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs ...